Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/535,000	HATANO ET AL.	
	Examiner	Art Unit	
	GIGI HUANG	1617	_
All Participants: Status of Application: <u>pre-appeal conference</u> , <u>after</u> <u>final rejection</u>			
(1) <u>GIGI HUANG</u> .	(3)		
(2) <u>RICHARD BARTH</u> .	(4)		
Date of Interview: <u>1 November 2010</u>	Time: <u>3:55pm</u>		
Type of Interview:			
Part I.			
Rejection(s) discussed:			
Claims discussed: 1, 5-12.			
Prior art documents discussed:			
Part II.  SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:  See Continuation Sheet			
Part III.			
<ul> <li>It is not necessary for applicant to provide a separate directly resulted in the allowance of the application. The of the interview in the Notice of Allowability.</li> <li>It is not necessary for applicant to provide a separate did not result in resolution of all issues. A brief summa</li> </ul>	ne examiner will provide a written record of the substance of the	en summary of the interview, since the	ne substance
/GiGi Huang/ Examiner, Art Unit 1617	Applicant/Applicant's Representat	ive Signature – if a	appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Discussed the allowance of the subject matter of claim 1 due to the evidence of synergism of the Rho kinase inhibitor (R)- (+)-N- (1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide with the ß-blocker is timolol in the reduction of the intraocular pressure. Discussed the rejoinder of claim 5 with amendments to be commensurate in scope with allowable claim 1, with cancellation of the remaining claims. Received call from Applicant agreeing to the amendments on November23, 2010.